School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China.
School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China.
Biomed Pharmacother. 2023 Dec 31;169:115891. doi: 10.1016/j.biopha.2023.115891. Epub 2023 Nov 16.
Lung cancer accounts for a relatively high proportion of malignant tumors. As the most prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high morbidity and mortality. Presently, the arsenal of treatment strategies encompasses surgical resection, chemotherapy, targeted therapy and radiotherapy. However, despite these options, the prognosis remains distressingly poor with a low 5-year survival rate. Therefore, it is urgent to pursue a paradigm shift in treatment methodologies. In recent years, the advent of sophisticated biotechnologies and interdisciplinary integration has provided innovative approaches for the treatment of lung cancer. This article reviews the cutting-edge developments in the nano drug delivery system, molecular targeted treatment system, photothermal treatment strategy, and immunotherapy for lung cancer. Overall, by systematically summarizing and critically analyzing the latest progress and current challenges in these treatment strategies of lung cancer, we aim to provide a theoretical basis for the development of novel drugs for lung cancer treatment, and thus improve the therapeutic outcomes for lung cancer patients.
肺癌在恶性肿瘤中占比较高。作为最常见的肺癌类型,非小细胞肺癌(NSCLC)具有高发病率和高死亡率的特点。目前,治疗策略包括手术切除、化疗、靶向治疗和放疗。然而,尽管有这些选择,预后仍然很差,5 年生存率低。因此,迫切需要在治疗方法上进行范式转变。近年来,复杂生物技术和跨学科融合的出现为肺癌的治疗提供了创新方法。本文综述了肺癌纳米药物传递系统、分子靶向治疗系统、光热治疗策略和免疫治疗的最新进展。总的来说,通过系统地总结和批判性地分析这些肺癌治疗策略的最新进展和当前挑战,我们旨在为肺癌治疗的新药开发提供理论依据,从而改善肺癌患者的治疗效果。
Biomed Pharmacother. 2023-12-31
Zhongguo Fei Ai Za Zhi. 2024-7-20
Curr Oncol Rep. 2020-3-5
Zhongguo Fei Ai Za Zhi. 2020-3-20
J Hematol Oncol. 2017-4-24
Radiol Clin North Am. 2012-9
Expert Opin Pharmacother. 2020-8-31
Psychiatry Clin Psychopharmacol. 2025-6-5